BIOTECH Logo

BIOTECH

BST | BME Growth

Overview

Corporate Details

ISIN(s):
ES0184980003 (+1 more)
LEI:
959800GNYT6ZZEWPEW29
Country:
Spain
Address:
AVDA. DEL DESARROLLO TECNOLOGICO (PARQUE CIENTIFICO TECNOLOGICO AGROINDUSTRIAL) 11, 11591 Jerez de la Frontera
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Biat Group is a biotechnology corporate group that operates through its holding company, Bionatur, and a global commercial network. The group is composed of several subsidiaries with distinct specializations. Biobide is a leading provider of preclinical research, offering toxicity and efficacy testing using the zebrafish (ZF) animal model. ZIP Solutions leverages a proprietary set of inteins for high-value applications in gene therapy, immunotherapy, in-vitro diagnostics (IVD), smart vaccines, and protein purification. The Bionatur division holds unique biotech assets for human and animal health. The group seeks collaborations in licensing, preclinical research, and vaccine improvement.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for BIOTECH. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-03-19 14:18
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-18 10:30
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-17 14:38
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-14 10:53
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-13 15:33
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-12 14:50
Net Asset Value
Net Asset Value(s)
English 4.1 KB
2025-03-11 15:54
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-10 14:35
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-07 14:28
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-07 09:08
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-06 15:30
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-06 08:00
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-05 14:34
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-04 14:40
Net Asset Value
Net Asset Value(s)
English 4.0 KB
2025-03-03 15:43
Net Asset Value
Net Asset Value(s)
English 4.0 KB

Automate Your Workflow. Get a real-time feed of all BIOTECH filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BIOTECH via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A